Alpha Tau Secures $35 Million in Tolmar Deal as Clinical Trials Advance
Event summary
- Alpha Tau completed a $35 million equity investment and manufacturing deal with Tolmar for U.S. prostate cancer commercialization.
- REGAIN trial for recurrent glioblastoma showed 100% local disease control and 67% complete response rate, clearing FDA to expand enrollment.
- ReSTART trial for recurrent cSCC completed patient enrollment, marking Alpha Tau's first fully enrolled U.S. pivotal study.
- Pancreatic cancer data presented at DDW 2026 and ASCO showed strong local disease control across multiple patient populations.
The big picture
Alpha Tau's strategic shift from a single-asset clinical story to a multi-indication platform gains traction with Tolmar's partnership and positive trial results. The $35 million upfront investment validates Alpha DaRT's potential in prostate cancer, while expanded FDA clearance for glioblastoma trials positions the company for broader oncology applications. With $104.8 million in cash reserves, Alpha Tau is well-positioned to capitalize on its dense sequence of upcoming milestones.
What we're watching
- Commercialization Pathway
- Whether Tolmar's $161.5 million in potential milestone payments can accelerate Alpha DaRT's U.S. market entry.
- Clinical Momentum
- The pace at which Alpha Tau can deliver year-end data readouts across multiple indications.
- Manufacturing Scaling
- How $15 million in expanded U.S. manufacturing capacity will support future commercial demand.
Related topics